Marcus A. Conant
Corporate Officer/Principal chez The University of California, San Francisco
Postes actifs de Marcus A. Conant
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | - | - |
Historique de carrière de Marcus A. Conant
Anciens postes connus de Marcus A. Conant
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - | - |
| ENZO BIOCHEM, INC. | Directeur/Membre du Conseil | - | - |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENZO BIOCHEM, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Presidio Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Marcus A. Conant
- Expérience
